, opens new tab will sell its remaining 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its consumer health business. Based on Kenvue stock's last ...
Tylenol maker Kenvue has said that Johnson & Johnson will sell its remaining 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its consumer health business.
The company logo for Kenvue Inc. Johnson & Johnson's consumer-health business, is displayed on during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2023.
Tylenol maker Kenvue said on Monday that Johnson & Johnson will offload its entire 9.5% stake in the company, about a year ...
Kenvue's shares were down 1.2% in premarket trading. J&J shares were largely unchanged. J&J finalized the biggest shake-up in its 137-year history to focus on its pharmaceutical and medical ...
(Reuters) -Tylenol maker Kenvue said on Monday that Johnson & Johnson will sell its remaining 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its consumer ...
(Reuters) – Tylenol maker Kenvue said on Monday that Johnson & Johnson will offload its entire 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its ...